Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1614 1618
This examiner grants 63% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17759729 | PLASMONICS SENSING NANOPLATFORMS FOR HUMAN STEM CELL APPLICATIONS AND METHODS THEREOF | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17998761 | CARBON NANOTUBES AND COMPLEXES THEREOF FOR TREATING AND DETECTING OCULAR TUMORS | Final Rejection | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18014729 | ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS | Non-Final OA | Hoffmann-La Roche Inc. |
| 18780262 | METHOD OF TREATMENT FOR SOLID TUMORS CONTAINING HYPOXIA AND/OR STROMA FEATURES | Non-Final OA | Wayne State University |
| 18753746 | PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES | Non-Final OA | TRANSLATE BIO, INC. |
| 18806385 | METHODS FOR TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES | Non-Final OA | Actinium Pharmaceuticals, Inc. |
| 17725544 | COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER | Non-Final OA | ACTINIUM PHARMACEUTICALS, INC. |
| 18751742 | Formulated and/or Co-Formulated Liposome Compositions Containing PD-1 Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof | Non-Final OA | Nammi Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy